Sclerostin deficiency leads to rare bone sclerosing disorders, while elevated levels of sclerostin are implicated in the pathogenesis of metabolic bone diseases like postmenopausal osteoporosis [117]. This evidence concerns the gene SOST and postmenopausal osteoporosis.